SeekInClarity®
Pan-cancer, pan-indication treatment response monitoring
Therapeutic efficacy monitoring is essential in cancer care, assessing tumor burden changes, treatment response, early drug resistance, and long-term efficacy. This enables personalized precision medicine to enhance outcomes and patient quality of life.
SeekInClarity® is a non-invasive, pan-cancer, pan-indication solution for advanced cancer patients. By detecting molecular signals earlier than traditional methods, it supports timely clinical decisions to improve patient outcomes.
Pan-cancer
Pan-indication
Early assessment
Progression prediction
Highlights
- Circulating tumor DNA (ctDNA) and proteins were analyzed from a single blood draw using a multiomics approach.
- Equipped with proprietary artificial intelligence (AI) and big data-driven molecular tumor burden (MTB) algorithms, it generates MTB scores that reflect cancer signals.
Testing time
Before treatment,
use to set a personalized baseline level.
After treatment,
compare with the baseline to check if the treatment is working well.
Early progression detection,
surveillance with greater sensitivity to detect cancer progression earlier than current standard of care tools.
Specifications
◉ Indicated subjects: patients who are diagnosed with advanced cancer
◉ Sample requirement: 8ml peripheral blood
◉ Result readout: molecular tumor burden (MTB)
◉ Turnaround time (TAT): 10 working days
By showing the increase or decrease in MTB between two tests, it reflects changes in cancer signals and highlights the effectiveness of treatment.
How it works
Customer order
Customers can place orders through SeekIn official website or local agents
Blood-draw
8 ml venous peripheral blood collected in cell-free DNA streck tube and can be stably stored at room temperature for 5 days
Testing
Detection by Roche cobas e411 instrument + next generation sequencing (NGS) platform
Reporting
The test results will be ready in about 10 workdays after your blood draw arrived at central lab
